Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill combo aims to cure hepatitis c in just 8 weeks

NCT ID NCT05904470

Disease control Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and results will show how safe and effective this short treatment course is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bemnifosbuvir and ruzasvir (oral antiviral drugs)
What this could lead to
If successful, this could provide a new, shorter treatment option for chronic hepatitis C, potentially curing the infection in most patients.
What could go wrong
This is a Phase 2 trial, so results are preliminary. The combination may not work for all hepatitis C genotypes or in patients with cirrhosis, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

275 people

The number who actually took part.

Started

May 2023

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent * Male or female subjects between ≥ 18 years of age (or the legal age of consent per local regulations) and ≤ 85 years of age * Female subjects of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to the use of an acceptable effective contraception * Females must have a negative pregnancy test at Screening and at Day 1 prior to dosing * Subjects must be direct-acting antiviral (DAA)-treatment-naïve, defined as never exposed to an approved or experimental DAA for HCV * Documented medical history compatible with chronic HCV * Liver disease staging assessment as follows: * Absence of cirrhosis (F0 to F3) * Compensated cirrhosis (F4) Exclusion Criteria: * Female subject is pregnant or breastfeeding * Co-infected with hepatitis B virus (HBV; positive for hepatitis B surface antigen \[HBsAg\]) and/or human immunodeficiency virus (HIV) * Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator * Prior exposure to any HCV DAA * Use of other investigational drugs within 30 days of dosing or plans to enroll in another clinical trial of an investigational agent while participating in the present study * Subject with known allergy to the study medications or any of their components * History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency * Cirrhotic and has a Child-Pugh score \>6, corresponding to a Child-Pugh Class B or C * History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC * Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis C virus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection cirrhosis of liver hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis C virus HCV Hepatic cirrhosis Hepatitis C Hepatitis C, chronic

Contacts and locations

Locations

  • Atea Study Site

    San Antonio, Texas, 78215, United States

  • Atea Study Site

    Manaus, Amazonas, 69040-000, Brazil

  • Atea Study Site

    Salvador, Estado de Bahia, 41920-900, Brazil

  • Atea Study Site

    Brasília, Federal District, 70200-730, Brazil

  • Atea Study Site

    Rio de Janeiro, Rio Do Janeiro, 04037-030, Brazil

  • Atea Study Site

    Porto Alegre, Rio Grande do Sul, 90035-074, Brazil

  • Atea Study Site

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Atea Study Site

    Porto Velho, Rondônia, 78918-791, Brazil

  • Atea Study Site

    Boa Vista, Roraima, 69304-015, Brazil

  • Atea Study Site

    Botucatu, São Paulo, 18618-970, Brazil

  • Atea Study Site

    Ijuí, São Paulo, 98700-000, Brazil

  • Atea Study Site

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Atea Study Site

    São Paulo, São Paulo, 04119-001, Brazil

  • Atea Study Site

    São Paulo, São Paulo, 05403-000, Brazil

  • Atea Study Site

    Sorocaba, São Paulo, 18052-210, Brazil

  • Atea Study Site

    Vancouver, British Columbia, V6Z 2C7, Canada

  • Atea Study Site

    Toronto, Ontario, M5G 2C4, Canada

  • Atea Study Site

    Rajkot, Gujarat, 360005, India

  • Atea Study Site

    Surat, Gujarat, 395002, India

  • Atea Study Site

    Belagavi, Karnataka, 590010, India

  • Atea Study Site

    Nagpur, Maharashtra, 440010, India

  • Atea Study Site

    Kolkata, West Bengal, 700020, India

  • Atea Study Site

    Quatre Bornes, 72218, Mauritius

  • Atea Study Site

    Chisinau, 2025, Moldova

  • Atea Study Site

    Karachi, 74800, Pakistan

  • Atea Study Site

    Karachi, 75600, Pakistan

  • Atea Study Site

    Baguio City, 35100, Philippines

  • Atea Study Site

    Iloilo City, 5000, Philippines

  • Atea Study Site

    Mabalacat, 2023, Philippines

  • Atea Study Site

    Bucharest, BUC, 022328, Romania

  • Atea Study Site

    Bucharest, BUC, 30303, Romania

  • Atea Study Site

    Constanța, CON, 900709, Romania

  • Atea Study Site

    Craiova, DOL, 200073, Romania

  • Atea Study Site

    Bucharest, 21105, Romania

  • Atea Study Site

    Bloemfontein, Free State, 9301, South Africa

  • Atea Study Site

    Johannesburg, Gauteng, 2193, South Africa

  • Atea Study Site

    Randburg, Gauteng, 2087, South Africa

  • Atea Study Site

    Somerset West, Western Cap, 7130, South Africa

  • Atea Study Site

    Seoul, Gyeonggi-do, 120-752, South Korea

  • Atea Study Site

    Yangsan, Gyeongsangnam, 626-770, South Korea

  • Atea Study Site

    Busan, 47392, South Korea

  • Atea Study Site

    Busan, 49241, South Korea

  • Atea Study Site

    Seoul, 5505, South Korea

  • Atea Study Site

    Seoul, 6351, South Korea

  • Atea Study Site

    Adana, 1130, Turkey (Türkiye)

  • Atea Study Site

    Ankara, 6100, Turkey (Türkiye)

  • Atea Study Site

    Ankara, 6230, Turkey (Türkiye)

  • Atea Study Site

    Ankara, 6800, Turkey (Türkiye)

  • Atea Study Site

    Denizli, 20070, Turkey (Türkiye)

  • Atea Study Site

    Izmir, 35100, Turkey (Türkiye)

  • Atea Study Site

    Kayseri, 38010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.